Milestones

May 2007	IPO: Initial Public offering completed raising A$50 million
November 2007	MoxDuo® IR: Phase 3 trials initiated with Dose Range Study
May 2008	MoxDuo IR: Dose Range study completed: Establishes Preferred Dose for Optimal Effi cacy and Tolerability; Study Goals and Secondary Endpoints Met (256 patients)
July 2008	MoxDuo IR: FDA accepts streamlined Phase 3 development programme: No Long Term Safety Data Required; Only Two Additional Phase 3 Studies for New Drug Application Submission
December 2008	MoxDuo IR: Initiation of "Combination Rule" Pilot Study
February 2009	MoxDuo IR: Initiation of Comparative Pilot Study in Pain after Total Knee Replacement
April 2009	MoxDuo IR: "Combination Rule" Pilot Study demonstrates that MoxDuo IR provides greater tolerability / fewer side effects than Morphine or Oxycodone alone (197 patients)
June 2009	MoxDuo IV: First patient dosed in Phase 2 Investigator study
August 2009	MoxDuo IR: Comparative Pilot Study in Pain after Total Knee Replacement demonstrates that MoxDuo® IR provides greater tolerability / fewer side effects than Percocet® (44 patients)
November 2009	MoxDuo IR: Initiate remaining MoxDuo IR Pivotal Phase 3 study programme

QRx Pharma